Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt

Sanofi broke ground on October 19, 2026, on a new insulin manufacturing facility at its BioCampus in Frankfurt, Germany, with full production of insulin API planned for 2032 once the facility is fully licensed.¹ Hesse Prime Minister Boris Rhein and Frankfurt Mayor Mike Josef joined Sanofi leaders at the groundbreaking ceremony, including CEO Belén Garijo, MD, PhD; Brendan O'Callaghan, executive vice president of manufacturing and supply; and Madeleine Roach, country president of Sanofi in Germany.¹

"Millions of people around the world rely on insulin every day, and our commitment to them is for the long term," said Dr Garijo in a company press release.¹ "With this new facility, we are investing in the next generation of insulin manufacturing in Europe, building on more than a century of expertise and a strong industrial footprint in Frankfurt. Maintaining the right conditions for investment and innovation will be essential to Europe's future competitiveness."

What will the new facility do?

The plant will be built on a 36,000-square-meter footprint at the Frankfurt BioCampus and is designed around high levels of automation, with digital technologies and artificial intelligence (AI) applied across manufacturing and quality processes.¹ Once operational, it will be among the largest insulin manufacturing facilities in Europe and part of Sanofi's global insulin supply network, according to the company.¹

The BioCampus already covers the full insulin manufacturing value chain, from API production to filling, device assembly, and packaging. Approximately 4000 employees at the site are dedicated to insulin, and about 20 insulin products are supplied from Frankfurt.¹

How is the project funded?

Sanofi announced plans for the facility in August 2024. At that time, Germany Trade & Invest, the German federal economic development agency, reported a planned investment of €1.3 billion (US$1.45 billion) and an expected operational date of 2029.²

On September 8, 2026, the European Commission (EC) approved €400 million (US$449) in German state aid to Sanofi-Aventis Deutschland GmbH as compensation for providing a service of general economic interest.³ Under the measure, Sanofi must build the new factory at Industriepark Frankfurt-Höchst by December 31, 2032. Through December 31, 2042, it must produce at least 1.1 tonnes of insulins per year at the site and stockpile 1 tonne of insulin API. It must also prioritize European Economic Area (EEA) markets during shortages.³ The EC said that without the aid, Sanofi would close its German site, leaving only 1 insulin production site in the EEA.³

Why does insulin manufacturing capacity matter?

According to the International Diabetes Federation's 2025 atlas, 589 million adults aged 20 to 79 years are living with diabetes, a number projected to reach 853 million by 2050.⁴ Sanofi supplies insulin to approximately 15 million people in more than 100 countries each year.¹ The Commission framed its approval as a measure to make the supply of human insulin and insulin analogues more resilient for patients in Germany.³

What are the limitations?

The groundbreaking marks the start of construction, and full API production depends on the facility being licensed. Sanofi's release did not disclose the total investment, annual output capacity, or which insulin products the new plant will manufacture. The 2032 full-production target is later than the 2029 operational date cited when the project was announced in 2024.² The company also did not detail how AI will be applied in manufacturing and quality processes. The EC's nonconfidential decision has not yet been published in its state aid register.³

References

1. Sanofi. Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany. Press release. Published October 19, 2026. Accessed October 21, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-10-19-10-30-00-3383205
2. Germany Trade & Invest. Germany attracts another billion-euro pharma project. Press release. Published August 1, 2024. Accessed October 21, 2026. https://www.prnewswire.com/news-releases/germany-attracts-another-billion-euro-pharma-project-302212375.html
3. European Commission. Commission approves €400 million German State aid to enhance insulin supply resilience. Press release IP/26/1798. Published September 8, 2026. Accessed October 21, 2026. https://ec.europa.eu/commission/presscorner/detail/nl/ip_26_1798
4. International Diabetes Federation. Over 250 million people worldwide unaware they have diabetes, according to new IDF research. Published April 7, 2025. Accessed October 21, 2026. https://idf.org/news-and-resources/news/idf-diabetes-atlas-11th-edition/